Aggressive surgical resection for concomitant liver and lung metastasis in colorectal cancer

Sung Hwan Lee¹, Sung Hyun Kim¹, Jin Hong Lim², Sung Hoon Kim³, Jin Gu Lee⁴, Dae Joon Kim⁴, Gi Hong Choi¹, Jin Sub Choi¹, and Kyung Sik Kim¹

¹Department of Surgery, Yonsei University College of Medicine, Seoul, ²Department of Surgery, Yongin Severance Hospital, Yongin, ³Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, ⁴Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea

Backgrounds/Aims: Aggressive surgical resection for hepatic metastasis is validated, however, concomitant liver and lung metastasis in colorectal cancer patients is equivocal. Methods: Clinicopathologic data from January 2008 through December 2012 were retrospectively reviewed in 234 patients with colorectal cancer with concomitant liver and lung metastasis. Clinicopathologic factors and survival data were analyzed. Results: Of the 234 patients, 129 (55.1%) had synchronous concomitant liver and lung metastasis from colorectal cancer and 36 (15.4%) had metachronous metastasis. Surgical resection was performed in 33 patients (25.6%) with synchronous and 6 (16.7%) with metachronous metastasis. Surgical resection showed better overall survival in both groups (synchronous, \( p = 0.001 \); metachronous, \( p = 0.028 \)). In the synchronous metastatic group, complete resection of both liver and lung metastatic lesions had better survival outcomes than incomplete resection of two metastatic lesions (\( p = 0.037 \)). The primary site of colorectal cancer and complete resection were significant prognostic factors (\( p = 0.06 \) and \( p = 0.003 \), respectively). Conclusions: Surgical resection for hepatic and pulmonary metastasis in colorectal cancer can improve complete resection and survival rate in resectable cases. Colorectal cancer with concomitant liver and lung metastasis is not a poor prognostic factor or a contraindication for surgical treatments, hence, an aggressive surgical approach may be recommended in well-selected resectable cases. (Korean J Hepatobiliary Pancreat Surg 2016;20:110-115)

Key Words: Colorectal cancer; Liver cancer; Lung cancer; Metastasis

INTRODUCTION

The liver is the most frequent site of metastatic colorectal cancer, and metastatic lesions from colorectal cancer are frequently detected in the lungs, bones, and brain. As surgical managements such as operative equipment innovation, operation strategy, and perioperative management have advanced, morbidity and mortality associated with surgical resection are reduced to acceptable levels. Since the first report of liver or lung metastasectomy due to colorectal cancer, surgical resection of liver and lung metastatic lesions is considered the only therapeutic option for long-term survival. In addition, perioperative chemotherapy improves the resectability of metastasectomy with minimal safety margins, which is an accepted standard procedure that is frequently performed worldwide. A safety resection margin of \( > 1 \) cm, or a 3-mm margin, is widely used for surgical resection of metastasis of colorectal cancer. Several clinical guidelines recommend surgical resection for synchronous or metachronous resectable metastatic lesions before or after systemic chemotherapy. However, the role of surgical resection in concomitant liver and lung metastasis is not clearly defined, and aggressive surgical resection may be a contributing factor in improvement of survival outcomes in patients with confirmed concomitant liver and lung metastasis. The aim of this study was to evaluate the efficacy of surgical resection in concomitant synchronous or...
metachronous liver and lung metastasis from colorectal cancer.

**MATERIALS AND METHODS**

**Patient selection**

Data regarding patients with liver and lung metastasis from colorectal cancer from January 2008 to December 2012 were reviewed retrospectively in our institutional cohort. Patients with concomitant liver and lung metastasis showing solitary or multiple lesions were then selected for the study, excluding non-surgical patients and patients with other metastasis besides liver and lung. Clinicopathologic and pathologic data was obtained and survival outcomes were analyzed in these patients (Fig. 1).

**Surgical procedures**

Liver and lung resections were performed by hepatobiliary surgeons and thoracic surgeons at a single institution. All surgical procedures were performed to completely remove the metastatic lesions in the liver or lung. Resections of the liver and lung were conducted for solitary or multiple lesions as one-step or two-step procedure based on the surgeons’ discretion.

**Follow-up and survival outcome**

Patients who underwent surgical resection for liver or lung metastatic lesions were examined regularly after surgery. Physical examination, blood test, and computed tomography (CT) scan of the abdomen and thorax were performed at each evaluation. Patients were followed until the latest visiting days, including the date of death or loss to follow-up.

**Statistics**

Continuous variables were expressed as mean±standard deviation and categorical variables were expressed as frequencies with percentages. The Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables were used to determine significant associations between parameters. The Kaplan-Meier method and log-rank test were used for survival analysis. Multivariate analysis using Cox-regression was done to identify significant prognostic factors for overall survival. Statistical significance was determined if the \( p \)-value was <0.05.

**RESULTS**

**Patient characteristics**

The age of patients with synchronous metastasis was

![Flow chart](image-url)
significantly higher than that of patients with metachronous metastasis, and female patients were frequently identified with metachronous metastasis. T stage, N stage, and location of primary colorectal cancer was not significantly different between synchronous and metachronous metastasis patients (Table 1).

**Detailed pattern of metastasis**

There were more liver lesions in synchronous than metachronous metastasis, without significant difference in largest size of solitary or multiple metastatic lesions between the two groups. In addition, synchronous metastasis showed multiple metastatic lesions in both liver lobes compared to metachronous metastasis, and the surgical method was not remarkably different between the two groups.

Multiple metastatic lesions of lung in the synchronous metastases were more frequent than in the metachronous metastasis, though size of lung metastases were not significantly different for either groups. Bilateral lung metastasis was more frequent in synchronous metastasis compared to metachronous metastasis, and the surgical method was not statistically different between both groups (Table 1).

---

**Table 1.** Clinicopathologic factors and detailed patterns of liver and lung metastasis in resected cases

|                      | Synchronous metastasis (n=33) | Metachronous metastasis (n=6) | p-value |
|----------------------|-------------------------------|-------------------------------|---------|
| **Age (range, median)** | 63 (29-78)                    | 46 (35-58)                    | 0.01    |
| **Sex (Male/Female)**  | 21 (63.6%)/12 (36.4%)         | 2 (33.3%)/4 (66.6%)           | 0.03    |
| **Preoperative CEA (ng/ml)** | 34.3 (3.4-85.4)               | 12.8 (2.5-56.3)               | 0.01    |
| **Primary CRC**       |                               |                               |         |
| **T stage (T1/T2/T3/T4)** | 0/3/26/4                     | 0/0/6/0                      | 0.686   |
| **N stage (N0/N1/N2)** | 9/12/12                      | 1/4/1                         | 0.147   |
| **Location**          |                               |                               |         |
| Colon                 | 17 (51.5%)                    | 2 (33.3%)                     | 0.124   |
| Rectum                | 16 (48.5%)                    | 4 (66.7%)                     |         |
| **Liver metastasis**  |                               |                               |         |
| Number of lesions     | 1-15 (7)                      | 1-3 (1)                       | 0.001   |
| (solitary/multiple)   | 6 (18.2%)/27 (81.8%)          | 4 (66.7%)/2 (33.3%)           |         |
| **Largest size (cm)** | 2.1 (0.8-4.5)                 | 2.4 (1.0-3.4)                 | 0.684   |
| **Distribution**      |                               |                               |         |
| Unilateral (Right/Left lobe) | 11 (33.3%)/7 (21.2%)     | 4 (66.6%)/2 (33.3%)           | 0.003   |
| Bilateral             | 15 (45.5%)                    | 0                              |         |
| **Operation**         |                               |                               |         |
| None                  | 2 (6.1%)                      | 1 (16.7%)                     | 0.576   |
| Wedge resection       | 18 (54.4%)                    | 2 (33.3%)                     |         |
| Segmentectomy         | 6 (18.2%)                     | 2 (33.3%)                     |         |
| Lobectomy             | 3 (9.1%)                      | 1 (16.7%)                     |         |
| Extended lobectomy    | 1 (3%)                        | 0                              |         |
| Intraoperative RFA    | 3 (9.1%)                      | 0                              |         |
| **Lung metastasis**   |                               |                               |         |
| Number of lesions     | 1-12 (5)                      | 1-2 (1)                       | 0.001   |
| (solitary/multiple)   | 12 (36.4%)/27 (63.6%)         | 5 (83.3%)/1 (16.7%)           |         |
| **Largest size (cm)** | 0.9 (0.5-3.1)                 | 1.0 (0.6-2.8)                 | 0.849   |
| **Distribution**      |                               |                               |         |
| Unilateral (Right/Left lobe) | 9 (27.3%)/7 (21.2%)  | 2 (33.3%)/4 (66.6%)           | 0.002   |
| Bilateral             | 17 (51.5%)                    | 0 (0%)                        |         |
| **Operation**         |                               |                               |         |
| None                  | 13 (39.4%)                    | 0 (0%)                        | 0.492   |
| Wedge resection       | 18 (54.5%)                    | 6 (100%)                      |         |
| Lobectomy             | 2 (6.1%)                      | 0 (0%)                        |         |
| Adjuvant treatment    | 13 (39.4%)                    | 2 (33.3%)                     | 0.824   |

SD, standard deviation; CEA, carcinoembryonic antigen; CRC, colorectal cancer; RFA, radiofrequency ablation
Clinical and oncologic outcomes

The median follow-up periods for synchronous and metachronous metastasis were 22.2 and 21.6 months, respectively, from the time of the operation. Preoperative adjuvant treatments were performed for 39.4% and 33.3% of patients in synchronous and metachronous groups, respectively. Complete surgical resections confirmed by postoperative imaging study were conducted for 54.6% and 83.3% of patients in each group. Unresected metastatic lesions in liver were treated by radiofrequency ablation (RFA) (Table 1).

There was no postoperative mortality within 30 days after operation (Table 2). Recurrence after surgical resection was 63.6% and 83.3% in the synchronous and metachronous groups, respectively. Survival analysis was performed using the Kaplan-Meier method and log-rank test. In the synchronous metastasis group, the resection group had statistically better survival, as compared to the non-resection group ($p<0.001$). Furthermore, complete resection of both liver and lung metastasis had significantly better survival than the incomplete resection group ($p=0.037$). Additionally, in the metachronous group, the resection group had significantly better survival, as compared to the non-resection group ($p=0.028$) (Fig. 2).

Prognostic factors

Multivariate analysis for prognostic factors of overall survival was performed using previously known prognostic factors and potential clinical markers. Rectal primary cancer was marginally significant ($p=0.06$, hazard ratio (HR)=0.988-2.318), and incomplete surgical resection for metastatic lesions was most significant ($p=0.003$, HR=1.477-6.441) for predicting poor outcomes in concomitant liver and lung metastasis from colorectal cancer (Table 3).

**DISCUSSION**

Colorectal cancer leads to metastatic disease in 60% of cases, with frequent involvement of the liver, lungs, or both. Following several reports of promising results after surgical resection of liver metastasis from colorectal cancer, the paradigm has shifted from limited indication for hepatic resection to an active surgical approach. Currently, the only absolute contraindication is the inability to obtain a tumor-free margin and maintain adequate liver function. Surgical resection is the only way to achieve long-term survival in patients with colorectal cancer liver metastases, and several comparative studies have revealed that surgical resection shows better survival outcomes, as compared to systemic chemotherapy alone.

Although several studies have explored optimal treatment strategies, there are still limitations for specific guidelines in a patient with synchronous or metachronous concomitant liver and lung metastasis from colorectal cancer. Treatment strategy differs between institutions.

---

**Table 2. Clinical course and recurrence pattern of resected cases**

|                              | Synchronous metastasis (n=33) | Metachronous metastasis (n=6) | $p$-value |
|------------------------------|-------------------------------|-------------------------------|----------|
| Follow-up period (median, range, month) | 22 (1-78)                    | 21 (2-38)                    | 0.547    |
| Adjuvant treatment           | 13 (39.4%)                    | 2 (33.3%)                    | 0.824    |
| Resection pattern            |                               |                               | 0.04     |
| Complete resection (Simultaneous/Staged) | 9 (27.3%)/9 (27.3%)          | 3 (50%)/2 (33.3%)            | 0.01     |
| Incomplete resection         | 15 (45.5%)                    | 1 (16.7%)                    | ns       |
| Postoperative CEA (POD 1 month, ng/ml) | 3.2 (1.9-12.4)               | 1.3 (1.2-7.2)                | 0.15     |
| Postoperative mortality      | 0 (0%)                        | 0 (0%)                       | ns       |
| Recurrence rate              | 21 (63.6%)                    | 5 (83.3%)                    | 0.652    |
| Recurrence interval (months, range) | 18 (3-79)                        | 22 (10-68)                  | 0.754    |
| Recurred site                |                               |                               |          |
| Liver                        | 4 (12.1%)                     | 2 (33.3%)                    |          |
| Lung                         | 3 (9.1%)                      | 0 (0%)                       |          |
| Liver+Lung                   | 8 (24.2%)                     | 0 (0%)                       |          |
| Carcinomatosis               | 3 (9.1%)                      | 1 (16.7%)                    |          |
| Other (Bone, brain, etc.)    | 3 (9.1%)                      | 2 (33.3%)                    |          |

CEA, carcinoembryonic antigen; POD, postoperative day
due to differing clinical situations of patients and the institute’s management plan. Nevertheless, several studies emphasize the importance of complete surgical resection in patients with concomitant liver and lung metastasis with colorectal cancer. In this study, the pattern of clinicopathologic factors, particularly the preoperative and postoperative levels of carcinoembryonic antigen (CEA), were evaluated for synchronous or metachronous metastasis from primary colorectal cancer. Although several clinical features differed based on the timing of metastasis from primary colorectal cancer, only complete resection of the metastatic liver and lung lesions improved survival outcomes.

The prognostic factors for liver and lung metastasis from colorectal cancer in terms of CEA, rectal primary cancer, bilateral lung metastasis, and multiple metastases...
have been recently reported. In particular, complete surgical resection of both liver and lung metastasis is the most significant prognostic factor for patients with concomitant liver and lung metastasis with colorectal cancer, according to a study on the synchronism of liver and lung metastasis. The resectability of liver and lung metastasis has gradually increased due to the progress in surgical skill and technique, and improvement of perioperative management. Recent advances in molecular biology have also offered new prognostic factors, e.g., KRAS, BRAF, NRAS, and PIK3CA mutations, for patients with metastatic colorectal cancer in the era of precision medicine.

This study has several limitations in terms of retrospective design, single-center study, and small study population. The heterogeneous clinical status of the enrolled population is another limitation. However, the evidence regarding the clinical situation for concurrent liver and lung metastasis in colorectal cancer is relatively rare and the strategy for this situation is not yet established. Therefore, this study increases our current understanding of concurrent liver and lung metastasis in colorectal cancer.

In conclusion, the results of this study indicated that the resection of hepatic and pulmonary metastases from colorectal cancer is safe and can offer long-term survival to selected patients. Surgery should be considered only if resection of all metastatic sites is potentially curative. Furthermore, resections should be as limited as possible to allow for repeat resections for eventual disease recurrence.

REFERENCES

1. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32.
2. van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 2015;32:457-465.
3. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducrueux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214-218.
4. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-1410.
5. Kumar R, Price TJ, Beeke C, Jain K, Patel G, Padbury R, et al. Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clin Colorectal Cancer 2014;13:87-93.
6. Konopke R, Kersting S, Makowicze F, Gassmann P, Kuhlisch E, Senninger N, et al. Resection of colorectal liver metastases: is a resection margin of 3 mm enough?: a multicenter analysis of the GAST Study Group. World J Surg 2008;32:2047-2056.
7. Nuzzo G, Giulianle F, Ardito F, Vellone M, Giovannini I, Federico B, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery 2008;143:384-393.
8. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:141-152.
9. Brouquet A, Vauthen JN, Contreras CM, Walsh GL, Vapniaczyan AA, Swisher SG, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg 2011;213:62-69.
10. Shah SA, Haddad R, Al-Sakhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006;202:468-475.
11. Arnaud JP, Dumont P, Adloff M, Leguillou A, Py JM. Natural history of colorectal carcinoma with untreated liver metastases. Surg Gastroenterol 1984;3:37-42.
12. D’Angelica MI, Correa-Gallego C, Pany PB, Cerneck A, Gewirtz AN, Chou JF, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015;261:353-360.
13. Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014;21:501-506.
14. Sourrouille I, Mordant P, Maggiiori L, Dokmak S, Lesèche G, Panis Y, et al. Long-term survival after hepatic and pulmonary resection of colorectal cancer metastases. J Surg Oncol 2013;108:220-224.
15. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014;29:1031-1042.
16. Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975-979.
17. Miller G, Biernacki P, Kenny NE, Gonen M, Downey R, Jarnagin WR, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007;205:231-238.
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
19. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015;22:834-842.